Document is current
Any future updates will be listed below
-
Authors
La Merrill, Michele A. https://orcid.org/0000-0002-5720-5862
Smith, Martyn T. https://orcid.org/0000-0003-1451-6377
McHale, Cliona M. https://orcid.org/0000-0002-8520-6117
Heindel, Jerrold J.
Atlas, Ella
Cave, Matthew C.
Collier, David https://orcid.org/0000-0002-3323-1900
Guyton, Kathryn Z.
Koliwad, Suneil
Nadal, Angel https://orcid.org/0000-0003-4178-2152
Rhodes, Christopher J. https://orcid.org/0000-0002-7450-1110
Sargis, Robert M. https://orcid.org/0000-0001-7061-2983
Zeise, Lauren
Blumberg, Bruce https://orcid.org/0000-0002-8016-8414
- License Information
-
More Information
Article History
Accepted: 28 October 2024
First Online: 29 November 2024
Competing interests
: M.T.S. has served as a paid consultant and expert witness in litigation involving chemical and pharmaceutical exposures and various disease outcomes that are unrelated to the present manuscript. M.T.S. is president and CEO of 1Tox and also conducts research in areas of interest similar to the business interests of 1Tox. R.M.S. declares he has received honoraria from CVS/Health that are unrelated to the present work. M.C.C. received research support and/or honoraria from Intercept Pharmaceuticals, Novo Nordisk, CymaBay Therapeutic, and Durect that are unrelated to the present work. C.J.R. is an employee of AstraZeneca and has shares in the company. All other authors declare no competing interests.
Free to read: This content has been made available to all.
